The antibody drug conjugate (ADC) development company, Glythera, has been granted exclusive, worldwide rights to Cancer Research UK’s novel CDK11 inhibitor programme for the development of multiple ADCs. more

28 Sep 2017 12:15 News

Contract testing organisation BioOutsource has amplified its position as a global leader in antibody drug conjugates (ADC) characterisation and announced a partnership with Glythera Ltd, an emerging biotechnology company based in Newcastle-upon... more

18 Feb 2014 10:13 Technology